Combining Statins with Radiotherapy for Prostate Cancer: From Photon Experience to Proton Potential

TL;DR

This paper explores combining statins with proton therapy for prostate cancer, building on their success with photon-based radiotherapy.

Contribution

The paper proposes a novel theoretical framework for combining statins with proton therapy based on mechanistic overlaps.

Findings

Statins improve outcomes in photon-based RT for prostate cancer.

Combining statins with proton therapy may offer enhanced therapeutic benefits.

Systematic testing is needed to validate the proposed synergy.

Abstract

Statins have shown promise as radiosensitizers in photon-based radiotherapy (RT), with studies demonstrating improved biochemical recurrence-free survival and reduced toxicity in prostate and other solid tumors. However, existing data derived entirely from photon-based RT and the potential synergy with proton therapy remain hypothetical at this stage. The current narrative review extrapolates the therapeutic benefits of statins observed in photon-based RT to proton therapy (PBT) to enhance therapeutic efficacy. The proposed combination of statins and PBT is a theoretical extension grounded in the mechanistic overlap between statin-induced radiosensitization and proton-specific advantages in dose conformity and linear energy transfer (LET). The hypothesis of enhanced synergy between statins and PBT warrants systematic preclinical testing and clinical trials before translation into standard practice.

Figures